TY - JOUR
T1 - Revisions to the staging and classification of mycosis fungoides and Sézary syndrome
T2 - A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
AU - Olsen, Elise
AU - Vonderheid, Eric
AU - Pimpinelli, Nicola
AU - Willemze, Rein
AU - Kim, Youn
AU - Knobler, Robert
AU - Zackheim, Herschel
AU - Duvic, Madeleine
AU - Estrach, Teresa
AU - Lamberg, Stanford
AU - Wood, Gary
AU - Dummer, Reinhard
AU - Ranki, Annamari
AU - Burg, Gunter
AU - Heald, Peter
AU - Pittelkow, Mark
AU - Bernengo, Maria Grazia
AU - Sterry, Wolfram
AU - Laroche, Liliane
AU - Trautinger, Franz
AU - Whittaker, Sean
PY - 2007/9/15
Y1 - 2007/9/15
N2 - The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and staging system for cutaneous T-cell lymphoma (CTCL). These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques as pertains to mycosis fungoides (MF) and Sézary syndrome (SS) since the 1979 publication of the original guidelines, to clarify certain variables that currently impede effective interinstitution and interinvestigator communication and/or the development of standardized clinical trials in MF and SS, and to provide a platform for tracking other variables of potential prognostic significance. Moreover, given the difference in prognosis and clinical characteristics of the non-MF/non-SS subtypes of cutaneous lymphoma, this revision pertains specifically to MF and SS. The evidence supporting the revisions is discussed as well as recommendations for evaluation and staging procedures based on these revisions.
AB - The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and staging system for cutaneous T-cell lymphoma (CTCL). These revisions are made to incorporate advances related to tumor cell biology and diagnostic techniques as pertains to mycosis fungoides (MF) and Sézary syndrome (SS) since the 1979 publication of the original guidelines, to clarify certain variables that currently impede effective interinstitution and interinvestigator communication and/or the development of standardized clinical trials in MF and SS, and to provide a platform for tracking other variables of potential prognostic significance. Moreover, given the difference in prognosis and clinical characteristics of the non-MF/non-SS subtypes of cutaneous lymphoma, this revision pertains specifically to MF and SS. The evidence supporting the revisions is discussed as well as recommendations for evaluation and staging procedures based on these revisions.
UR - http://www.scopus.com/inward/record.url?scp=34548849451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548849451&partnerID=8YFLogxK
U2 - 10.1182/blood-2007-03-055749
DO - 10.1182/blood-2007-03-055749
M3 - Review article
C2 - 17540844
AN - SCOPUS:34548849451
SN - 0006-4971
VL - 110
SP - 1713
EP - 1722
JO - Blood
JF - Blood
IS - 6
ER -